Breast Care最新文献

{"title":"Patient Preferences for HR+/HER2- Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment.","authors":"Victoria Harmer, Cathy Ammendolea, Mandy Ryan, Frances Boyle, Gustavo Werutsky, Dina El Mouzain, Deborah A Marshall, Caitlin Thomas, Sebastian Heidenreich, Hui Lu, Nicolas Krucien, Juan Mora Payan, Dawn Aubel, Andriy Danyliv, Purnima Pathak, Nadia Harbeck","doi":"10.1159/000543320","DOIUrl":"10.1159/000543320","url":null,"abstract":"<p><strong>Introduction: </strong>More adjuvant treatment options are becoming available for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) based on results of clinical trials. This study quantified the importance of different attributes of EBC adjuvant therapies to patients and the benefit-risk tradeoffs patients were willing to make.</p><p><strong>Methods: </strong>Women with HR+/HER2- EBC completed an online discrete choice experiment (DCE) survey; the design was informed by clinical data, qualitative interviews (<i>n</i> = 40), and pre-testing interviews (<i>n</i> = 40). Participants (pts) made 10 choices between pairs of hypothetical treatments described by varying levels of 6 attributes. DCE data were analyzed using a correlated mixed logit model. Relative attribute importance scores captured the impact of each attribute across clinically relevant ranges. Benefit-risk tradeoffs were captured as the minimum improvements in 5-year invasive disease-free survival (iDFS) that pts would require to tolerate increases in therapy-associated adverse event (AE) risks.</p><p><strong>Results: </strong>A total of 866 patients from the USA, France, Spain, Canada, the UK, Germany, South Korea, and Australia completed the DCE (mean age: 57.7 years; 76% postmenopausal; 29% stage I disease, 55% stage II, 16% stage III). Improved 5-year iDFS (75.4-82.7% range; associated with combination regimens [CRs] vs. endocrine therapy [ET] alone) contributed the most to treatment preferences (clinically relevant relative attribute importance: 38.4%), followed by reduced risks of venous thromboembolic events (VTEs) (20.4%), neutropenia (20.3%), and diarrhea (15.0%). Treatment type + duration (3.7%) and fatigue (2.3%) were less important. Pts required the largest improvement in 5-year iDFS (3.9%) to tolerate increased risks of VTE (0.7%-2.5%) or neutropenia (5.6%-46%); willingness to accept tradeoffs depended on the AE. Preference heterogeneity was observed across subgroups, but 5-year iDFS improvement was consistently the most impactful on treatment choice in all subgroups.</p><p><strong>Conclusion: </strong>A multicountry sample of patients most valued adjuvant therapies with higher 5-year iDFS and may therefore prefer CRs over ET alone. The value of CRs depends on their specific safety profiles, and shared decision-making should consider this to select treatment options that align with individual preferences.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"16-26"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Discussion: ESMO 2024.","authors":"Christoph Thomssen, Maggie Banys-Paluchowski, François-Clément Bidard, Nancy U Lin","doi":"10.1159/000543115","DOIUrl":"https://doi.org/10.1159/000543115","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"40-44"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Importance of Panimmune-Inflammation Value and PILE Scores in Non-Metastatic Luminal A Breast Cancer.","authors":"Mukaddes Yılmaz, Eda Erdiş, Mahmut Uçar, Birsen Yücel","doi":"10.1159/000543304","DOIUrl":"10.1159/000543304","url":null,"abstract":"<p><strong>Introduction: </strong>The present study evaluated the prognostic significance of panimmune-inflammation value (PIV) and PILE (a composite score of PIV, lactate dehydrogenase [LDH], and Eastern Cooperative Oncology Group Performance Status [ECOG PS]) in patients with non-metastatic luminal A breast cancer.</p><p><strong>Methods: </strong>Non-metastatic stage (I-III) luminal A breast cancer patients who were admitted to Cumhuriyet University Oncology Center were retrospectively examined. The PIV score was calculated using the neutrophil, platelet, monocyte, and lymphocyte counts at the time of diagnosis. The PIV, LDH, and ECOG PS parameters were used for the PILE score.</p><p><strong>Results: </strong>A total of 293 patients were included. The median PIV was 254.89; 239 (82%) patients had low PILE score; and 54 (18%) patients had high PILE score. Patients with low PIV and low PILE scores had significantly better OS and disease-free survival (DFS) (PIV; <i>p</i> = 0.033 for OS and <i>p</i> = 0.024 for DFS and PILE; <i>p</i> = 0.001 for OS and <i>p</i> = 0.005 for DFS). The PIV and PILE scores were found to be significant prognostic factors associated with OS and DFS. The PIV score was found to be an independent prognostic factor for OS and DFS (OS: score 0 vs. 1; HR: 1.89, 95% CI: 1.06-3.35; <i>p</i> = 0.029; and DFS: score 0 vs. 1; HR: 1.75, 95% CI: 1.01-3.01; <i>p</i> = 0.044). The PILE score was not an independent prognostic factor associated with OS or DFS.</p><p><strong>Conclusion: </strong>Survival was better in those with lower PIV and PILE scores. The PIV score was an independent prognostic factor for survival in these patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"27-39"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors for Upgrade to Breast Cancer in Patients with B3 Lesions Diagnosed by Core Biopsy: A Retrospective Cohort Study.","authors":"Burak Dinçer, Ceylan Yanar, Ramazan Uçak, Esma Çerekçi, Cemal Kaya","doi":"10.1159/000542551","DOIUrl":"10.1159/000542551","url":null,"abstract":"<p><strong>Background: </strong>The optimal approach to B3 lesions is controversial, and the risk of malignant upgrade varies between studies. This study aimed to evaluate the factors affecting the risk of upgrading to breast cancer in patients diagnosed with B3 lesions by core biopsy.</p><p><strong>Methods: </strong>A total of 410 patients diagnosed with B3 lesions by core biopsy and subsequently undergoing surgical excision were evaluated. Patients who did not undergo surgical excision or were not followed up at our center were excluded. Patients were analyzed based on demographic, clinical, radiological, and pathological findings.</p><p><strong>Results: </strong>All 410 patients included in the study were women, with a median age of 47 years (range 21-78). An upgrade to in situ or invasive disease was observed in 117 of the 410 patients (28.5%). In univariate analysis, age, mammographic findings, histopathological type, and atypia in core biopsy were identified as significant factors affecting the upgrade rate (<i>p</i> = 0.046, <i>p</i> = 0.028, <i>p</i> < 0.001, and <i>p</i> < 0.001, respectively). In multivariate analysis, the presence of atypia (<i>p</i> < 0.001) and a diagnosis of atypical ductal hyperplasia (ADH) (<i>p</i> = 0.026) were determined to be independent variables that increase the upgrade rate.</p><p><strong>Conclusion: </strong>Surgical excision or vacuum-assisted excision may be more appropriate for ADH and B3 lesions with atypia on core biopsy.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"1-7"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights from the San Antonio Breast Cancer Symposium 2024.","authors":"Isabell Witzel, Mattea Reinisch, Gabriel Rinnerthaler, Cornelia Leo","doi":"10.1159/000543369","DOIUrl":"https://doi.org/10.1159/000543369","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"45-50"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the Need for Breast Imaging in Young Women with Clinically Significant Breast Pain and a Normal Physical Breast Examination.","authors":"Noa Rotbart, Oleg Kaminsky, David Aranovich, Tzipora Shochat, Eli Atar, Ahuva Grubstein","doi":"10.1159/000543437","DOIUrl":"10.1159/000543437","url":null,"abstract":"<p><strong>Introduction: </strong>Although breast pain as a sole symptom is very rarely associated with cancer, national guidelines recommend that all women with a complaint of breast pain have to be referred for ultrasound evaluation. This study sought to investigate the necessity of this practice.</p><p><strong>Methods: </strong>A retrospective study was conducted in consecutive women aged between 17 and 39 years, at average risk of breast cancer who presented at a major tertiary breast clinic with clinically significant breast pain (unilateral, unifocal, and noncyclic) in 2017-2023. Data on background, physical examination, imaging, and pathology were collected from the electronic medical records and analyzed by outcome.</p><p><strong>Results: </strong>The cohort included 814 women. Among the 574 women (70%) with a normal physical breast examination, ultrasound revealed normal findings or BI-RADS 1-2 lesions in 499 (87%), BI-RADS 3 lesions in 59 (10%), and BI-RADS 4 lesions in 16 (3%). Biopsies, performed in 30 BI-RADS 3 lesions and all BI-RADS 4 lesions, were benign. Half of the 337 patients with available follow-up data continued to attend the breast clinic (mean 3.5 ± 2.2 years). Among the 240 women (30%) with a palpable abnormality on breast examination, ultrasound revealed normal or benign BI-RADS 2 findings in 112 (47%), BI-RADS 3 lesions in 69 (29%), and BI-RADS 4-5 lesions in 59 (25%). Biopsies performed in BI-RADS 3 lesions (12%) were all benign. Biopsies, performed in all BI-RADS 4-5 lesions, yielded malignant pathology in 16 lesions (7%) (including IDC, DCIS, or angiosarcoma). The overall breast cancer risk was 2%. Ultrasound sensitivity was 94%, specificity 85%, and negative predictive value 99%. The negative predictive value for dedicated physical examination without imaging was 100%. The biopsy-proven positive predictive value was 0 in patients with a normal breast examination compared to 18% in patients with a palpable finding on breast examination (<i>p</i> = 0.0017).</p><p><strong>Conclusion: </strong>A subset of women <40 years old with average breast cancer risk and breast pain, who would normally be referred for imaging, can be triaged by a dedicated physical examination. Limiting ultrasound evaluation to those with palpable findings will spare patients and the healthcare system unnecessary radiology and biopsy studies.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"8-15"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast-Conserving Surgery with Immediate Partial Breast Reconstruction by Using Pedicled Thoracodorsal Artery Perforator Flap: A 7-Year Follow-Up of 50 Women.","authors":"Xing Wang, Ling Huo, Yingjian He, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tao Ouyang","doi":"10.1159/000541340","DOIUrl":"10.1159/000541340","url":null,"abstract":"<p><strong>Introduction: </strong>Thoracodorsal artery perforator (TDAP) flap has been used for more than 10 years in the immediate partial breast reconstruction (IPBR) of breast cancer, allowing many patients to maximize reserved autologous breast tissue who do not have indications for breast-conserving surgery (BCS). No large sample size survival data for this operation have been reported worldwide.</p><p><strong>Methods: </strong>There are 212 primary breast cancer patients who were prepared to receive BCS with IPBR of pedicled TDAP flaps in our institution from June 2013 to December 2017. Finally, the operations were completed successfully in 50 cases. All patients were female with a median age of 40 years.</p><p><strong>Results: </strong>The average diameter of TDAPs measured by Doppler ultrasound before the operation was 1.8 ± 0.6 mm (ranging from 0.6 to 3.3 mm). The average size of the flaps was 15 × 6 cm. The average time of operations was 282 ± 71 min (ranging from 120 to 425 min). The drainage tube was removed 4.8 ± 1.9 days after the operation (ranging from 3 to 12 days). All TDAP flaps survived, and the wound complication rate was 4% (2/50). The median follow-up time was 88 (67, 94) months (M [IQR]), with a 5-year ipsilateral breast tumor recurrence rate of 4% (95% CI: 0.1-9.5%), a 5-year breast cancer-free interval of 88.0% (95% CI: 79.0-97.0%), and a 5-year overall survival rate of 96.0% (95% CI: 90.5-99.9%).</p><p><strong>Conclusion: </strong>IPBR using pedicled TDAP flaps is a good choice for repairing local breast defects in BCS. The advantages of this surgery are no influence on latissimus dorsi function, few complications in the donor area, and good long-term prognosis.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"19 6","pages":"297-306"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Efficacy of Intralesional Injection versus Systemic Steroids in Treating Idiopathic Granulomatous Mastitis: Insights from a Single-Center Experience.","authors":"Buşra Burcu, Işık Çetinoğlu, Nadir Adnan Hacim, Esma Çerekçi, Aziz Şener, Ramazan Uçak, Ceylan Yanar, Cemal Kaya","doi":"10.1159/000541707","DOIUrl":"10.1159/000541707","url":null,"abstract":"<p><strong>Objective: </strong>Idiopathic granulomatous mastitis (IGM) is a benign inflammatory condition predominantly affecting women of reproductive age, particularly those with a history of breastfeeding. Although the precise etiology remains unknown, treatment strategies continue to be a subject of debate. This study aimed to compare the efficacy of intralesional steroid (ILS) injections with oral steroid (OS) therapy in managing IGM.</p><p><strong>Materials and methods: </strong>A total of 72 patients, clinically and histopathologically diagnosed with IGM, were treated with either ILSs (group ILS, <i>n</i> = 47) or OSs (group OS, <i>n</i> = 25) at a tertiary referral hospital between January 2022 and January 2024. The data were retrospectively analyzed.</p><p><strong>Results: </strong>The mean age of the patients was 33.5 years (range: 22-56). No statistically significant differences were observed between the two groups in terms of demographic characteristics, presenting symptoms, clinical findings, or laboratory results. The mean treatment duration was 6 months. There were no significant differences in treatment response or recurrence rates between the two groups. However, there was a statistically significant difference in the incidence of side effects, with 6.3% in the ILS group compared to 36% in the OS group (<i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>Given its ease of application, lower incidence of side effects, and comparable efficacy, ILS injections may be considered a first-line treatment option in the management of IGM.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"19 6","pages":"307-315"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Impact of Sarcopenia on Mortality in Breast Cancer Patients: A Comprehensive Systematic Review and Meta-Analysis.","authors":"YanYan Dai, Jiarong Lan, Shasha Li, Guangxing Xu","doi":"10.1159/000541421","DOIUrl":"10.1159/000541421","url":null,"abstract":"<p><strong>Background: </strong>This study assesses the frequency of sarcopenia in patients with breast cancer (BC) and its association with mortality rates.</p><p><strong>Methods: </strong>An all-encompassing search across (PubMed, Scopus, Web of Science, and CINAHL) was done, to identify studies, published until August 2023, that report data on sarcopenia and mortality in BC patients. A meta-analysis was then done using a random-effects model.</p><p><strong>Results: </strong>Out of 989 initially identified potential studies, 19 met inclusion criteria. Analysis of 15 studies showed a rate of sarcopenia of 38% (95% CI: 29-48%), with moderate heterogeneity (<i>I</i> ² = 25.8%). Sarcopenia was linked to increased mortality risk in BC patients across 16 studies (HR: 1.77, CI: 1.35-2.32, <i>p</i> = <0.001) with both shorter and longer follow-up periods. Similarly, mortality risks were significantly higher in metastatic (HR: 1.52, CI: 1.14-2.03, <i>p</i> = 0.004) and non-metastatic (HR: 2.55, CI: 1.66-3.93, <i>p</i> < 0.001) BC patients with sarcopenia.</p><p><strong>Conclusion: </strong>Our analysis demonstrates a substantial prevalence of sarcopenia in BC patients. Importantly, sarcopenia was significantly linked to an elevated risk of mortality in this population. Subgroup analyses, stratified by follow-up periods and disease stage, consistently reveal increased mortality risks associated with sarcopenia, underscoring its clinical relevance in both short- and long-term patient outcomes. Our findings further strengthen the need to recognize and address sarcopenia as a critical factor in BC management and prognosis.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"19 6","pages":"316-328"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Impact of COVID-19 Pandemic on Primary Breast Cancer Care.","authors":"Maximilian Pruss, Melissa Neubacher, Frederic Dietzel, Natalia Krawczyk, Jan-Philipp Cieslik, Svjetlana Mohrmann, Eugen Ruckhäberle, Elisabeth C Sturm-Inwald, Tanja N Fehm, Bianca Behrens","doi":"10.1159/000541015","DOIUrl":"https://doi.org/10.1159/000541015","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has transformed breast cancer care for patients and healthcare providers. Circumstances varied greatly by region and hospital, depending on COVID-19 prevalence, case mix, hospital type, and available resources. These challenges have disrupted screening programs and have been particularly distressing for both women with a breast cancer diagnosis and their providers.</p><p><strong>Summary: </strong>This review explores the retrospective impact of the COVID-19 pandemic on primary breast cancer care. It analyzes changes in screening participation, diagnosis rates, treatment modalities, and the delivery of psycho-oncological support during the pandemic. The study found a significant reduction in breast cancer screenings and a subsequent stage shift in diagnoses, with fewer early-stage and more advanced-stage cancers being detected. Additionally, the review discusses the psychosocial challenges faced by patients and the adaptations made in care delivery, such as the increased use of telemedicine. Despite these challenges, the healthcare systems showed resilience, with core treatment services largely maintained and rapid adaptations to new care models.</p><p><strong>Key messages: </strong>There was a marked decrease in breast cancer screenings and early diagnoses during the pandemic, with a shift toward more advanced-stage detections. While there was an increased use of neoadjuvant therapies and telemedicine, essential breast cancer treatments were mostly sustained, reflecting the resilience of healthcare systems. The pandemic significantly impacted the mental health of breast cancer patients, exacerbating anxiety and depression and highlighting the need for improved psycho-oncological support. The full impact of these disruptions on long-term breast cancer outcomes remains uncertain, necessitating ongoing monitoring and adaptation of care strategies to mitigate adverse effects.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"19 5","pages":"270-281"},"PeriodicalIF":2.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}